211 related articles for article (PubMed ID: 38424542)
1. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
3. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
4. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
[TBL] [Abstract][Full Text] [Related]
6. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
9. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
10. Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α.
Hartley G; Regan D; Guth A; Dow S
Cancer Immunol Immunother; 2017 Apr; 66(4):523-535. PubMed ID: 28184968
[TBL] [Abstract][Full Text] [Related]
11. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
[TBL] [Abstract][Full Text] [Related]
12. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
LaMarche NM; Hegde S; Park MD; Maier BB; Troncoso L; Le Berichel J; Hamon P; Belabed M; Mattiuz R; Hennequin C; Chin T; Reid AM; Reyes-Torres I; Nemeth E; Zhang R; Olson OC; Doroshow DB; Rohs NC; Gomez JE; Veluswamy R; Hall N; Venturini N; Ginhoux F; Liu Z; Buckup M; Figueiredo I; Roudko V; Miyake K; Karasuyama H; Gonzalez-Kozlova E; Gnjatic S; Passegué E; Kim-Schulze S; Brown BD; Hirsch FR; Kim BS; Marron TU; Merad M
Nature; 2024 Jan; 625(7993):166-174. PubMed ID: 38057662
[TBL] [Abstract][Full Text] [Related]
13. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
14. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
Taube JM; Young GD; McMiller TL; Chen S; Salas JT; Pritchard TS; Xu H; Meeker AK; Fan J; Cheadle C; Berger AE; Pardoll DM; Topalian SL
Clin Cancer Res; 2015 Sep; 21(17):3969-76. PubMed ID: 25944800
[TBL] [Abstract][Full Text] [Related]
16. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
17. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
18. The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy.
Zhang Y; Ma L; Hu X; Ji J; Mor G; Liao A
Hum Reprod; 2019 Jan; 34(1):25-36. PubMed ID: 30500923
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
Front Immunol; 2022; 13():954039. PubMed ID: 36131912
[TBL] [Abstract][Full Text] [Related]
20. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
